Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1984 Feb;49(2):490–496. doi: 10.1128/jvi.49.2.490-496.1984

Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons.

C W Czarniecki, C W Fennie, D B Powers, D A Estell
PMCID: PMC255490  PMID: 6319748

Abstract

The antiviral and antiproliferative effects of highly purified Escherichia coli-derived human interferons (IFNs) were examined in human melanoma cells (Hs294T). Antiproliferative activity was monitored by measuring inhibition of cell multiplication, and antiviral activity was determined by inhibition of herpes simplex virus type 1 replication. Treatment of cells with IFN-gamma in combination with IFN-alpha A or IFN-beta 1 resulted in potentiation of both antiproliferative and antiviral activities. In contrast, combination treatments composed of IFN-alpha A and IFN beta 1 yielded inconsistent results. Some combinations reflected additive responses, whereas others were antagonistic. To examine correlations between IFN-induced biological activities and interactions of the different IFNs with cell surface receptors, in vivo [35S]methionine-labeled IFN-alpha A was prepared. Binding studies indicated the presence of 2,980 +/- 170 receptors per cell, each with an apparent Kd of (8.4 +/- 1.3) X 10(-11) M. Results from competitive binding studies suggested that Hs294T cells possess at least two types of IFN receptors: one which binds IFN-alpha A and IFN-beta 1 and another to which IFN-gamma binds.

Full text

PDF
490

Images in this article

494Image
on p.494

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguet M., Belardelli F., Blanchard B., Marcucci F., Gresser I. High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse gamma interferon and cholera toxin do not compete for the common receptor site of alpha / beta interferon. Virology. 1982 Mar;117(2):541–544. doi: 10.1016/0042-6822(82)90497-4. [DOI] [PubMed] [Google Scholar]
  2. Aguet M., Blanchard B. High affinity binding of 125I-Labeled mouse interferon to a specific cell surface receptor. II. Analysis of binding properties. Virology. 1981 Dec;115(2):249–261. doi: 10.1016/0042-6822(81)90108-2. [DOI] [PubMed] [Google Scholar]
  3. Aguet M. High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor. Nature. 1980 Apr 3;284(5755):459–461. doi: 10.1038/284459a0. [DOI] [PubMed] [Google Scholar]
  4. Anderson P., Yip Y. K., Vilcek J. Specific binding of 125I-human interferon-gamma to high affinity receptors on human fibroblasts. J Biol Chem. 1982 Oct 10;257(19):11301–11304. [PubMed] [Google Scholar]
  5. Ankel H., Krishnamurti C., Besançon F., Stefanos S., Falcoff E. Mouse fibroblast (type I) and immune (type II) interferons: pronounced differences in affinity for gangliosides and in antiviral and antigrowth effects on mouse leukemia L-1210R cells. Proc Natl Acad Sci U S A. 1980 May;77(5):2528–2532. doi: 10.1073/pnas.77.5.2528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bourgeade M. F., Chany C., Merigan T. C. Type I and type II interferons: differential antiviral actions in transformed cells. J Gen Virol. 1980 Feb;46(2):449–454. doi: 10.1099/0022-1317-46-2-449. [DOI] [PubMed] [Google Scholar]
  7. Branca A. A., Baglioni C. Evidence that types I and II interferons have different receptors. Nature. 1981 Dec 24;294(5843):768–770. doi: 10.1038/294768a0. [DOI] [PubMed] [Google Scholar]
  8. Crane J. L., Jr, Glasgow L. A., Kern E. R., Youngner J. S. Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst. 1978 Sep;61(3):871–874. [PubMed] [Google Scholar]
  9. Creasey A. A., Smith H. S., Hackett A. J., Fukuyama K., Epstein W. L., Madin S. H. Biological properties of human melanoma cells in culture. In Vitro. 1979 May;15(5):342–350. doi: 10.1007/BF02616140. [DOI] [PubMed] [Google Scholar]
  10. Dianzani F., Zucca M., Scupham A., Georgiades J. A. Immune and virus-induced interferons may activate cells by different derepressional mechanisms. Nature. 1980 Jan 24;283(5745):400–402. doi: 10.1038/283400a0. [DOI] [PubMed] [Google Scholar]
  11. Evinger M., Maeda S., Pestka S. Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem. 1981 Mar 10;256(5):2113–2114. [PubMed] [Google Scholar]
  12. Fleischmann W. R., Jr, Georgiades J. A., Osborne L. C., Johnson H. M. Potentiation of interferon activity by mixed preparations of fibroblast and immune interferon. Infect Immun. 1979 Oct;26(1):248–253. doi: 10.1128/iai.26.1.248-253.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fleischmann W. R., Jr Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence. Cancer Res. 1982 Mar;42(3):869–875. [PubMed] [Google Scholar]
  14. Goeddel D. V., Leung D. W., Dull T. J., Gross M., Lawn R. M., McCandliss R., Seeburg P. H., Ullrich A., Yelverton E., Gray P. W. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature. 1981 Mar 5;290(5801):20–26. doi: 10.1038/290020a0. [DOI] [PubMed] [Google Scholar]
  15. Goeddel D. V., Shepard H. M., Yelverton E., Leung D., Crea R., Sloma A., Pestka S. Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Res. 1980 Sep 25;8(18):4057–4074. doi: 10.1093/nar/8.18.4057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Goeddel D. V., Yelverton E., Ullrich A., Heyneker H. L., Miozzari G., Holmes W., Seeburg P. H., Dull T., May L., Stebbing N. Human leukocyte interferon produced by E. coli is biologically active. Nature. 1980 Oct 2;287(5781):411–416. doi: 10.1038/287411a0. [DOI] [PubMed] [Google Scholar]
  17. Gray P. W., Leung D. W., Pennica D., Yelverton E., Najarian R., Simonsen C. C., Derynck R., Sherwood P. J., Wallace D. M., Berger S. L. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 1982 Feb 11;295(5849):503–508. doi: 10.1038/295503a0. [DOI] [PubMed] [Google Scholar]
  18. Hovanessian A. G., La Bonnardiere C., Falcoff E. Action of murine gamma (immune)interferon on beta (fibroblast)-interferon resistant L 1210 and embryonal carcinoma cells. J Interferon Res. 1980 Fall;1(1):125–135. doi: 10.1089/jir.1980.1.125. [DOI] [PubMed] [Google Scholar]
  19. Interferon nomenclature. Nature. 1980 Jul 10;286(5769):110–110. doi: 10.1038/286110a0. [DOI] [PubMed] [Google Scholar]
  20. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  21. Neidhardt F. C., Wirth R., Smith M. W., Van Bogelen R. Selective synthesis of plasmid-coded proteins by Escherichia coli during recovery from chloramphenicol treatment. J Bacteriol. 1980 Jul;143(1):535–537. doi: 10.1128/jb.143.1.535-537.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Redpath J. L. Mechanisms in combination therapy: isobologram analysis and sequencing. Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Sep;38(3):355–356. doi: 10.1080/09553008014551711. [DOI] [PubMed] [Google Scholar]
  23. Rubin B. Y., Gupta S. L. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci U S A. 1980 Oct;77(10):5928–5932. doi: 10.1073/pnas.77.10.5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Staehelin T., Hobbs D. S., Kung H., Lai C. Y., Pestka S. Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. J Biol Chem. 1981 Sep 25;256(18):9750–9754. [PubMed] [Google Scholar]
  25. Steel G. G., Peckham M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85–91. doi: 10.1016/0360-3016(79)90044-0. [DOI] [PubMed] [Google Scholar]
  26. Streuli M., Nagata S., Weissmann C. At least three human type alpha interferons: structure of alpha 2. Science. 1980 Sep 19;209(4463):1343–1347. doi: 10.1126/science.6158094. [DOI] [PubMed] [Google Scholar]
  27. Wetzel R., Perry L. J., Estell D. A., Lin N., Levine H. L., Slinker B., Fields F., Ross M. J., Shively J. Properties of a human alpha-interferon purified from E. coli extracts. J Interferon Res. 1981;1(3):381–390. doi: 10.1089/jir.1981.1.381. [DOI] [PubMed] [Google Scholar]
  28. Zerial A., Hovanessian A. G., Stefanos S., Huygen K., Werner G. H., Falcoff E. Synergistic activities of type I (alpha, beta) and type II (gamma) murine interferons. Antiviral Res. 1982 Sep;2(4):227–239. doi: 10.1016/0166-3542(82)90045-6. [DOI] [PubMed] [Google Scholar]
  29. Zoon K., Zur Nedden D., Arnheiter H. Specific binding of human alpha interferon to a high affinity cell surface binding site on bovine kidney cells. J Biol Chem. 1982 May 10;257(9):4695–4697. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES